世界の静脈注射用鉄剤市場2023-2030:製品別(鉄デキストラン、鉄スクロース鉄、カルボキシマルトース第2鉄)、用途別(慢性腎臓病、炎症性腸疾患、がん)、地域別

【英語タイトル】Intravenous Iron Drugs Market Size, Share & Trends Analysis Report By Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料(GRV23JUN062)・商品コード:GRV23JUN062
・発行会社(調査会社):Grand View Research
・発行日:2023年5月15日
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥892,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,042,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,342,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の静脈注射用鉄剤市場規模が、予測期間中に年平均8.6%増加し、2030年までに56.4億ドルへ達すると見込まれています。本調査書では、静脈注射用鉄剤の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、産業の展望、製品別(鉄デキストラン、鉄スクロース鉄、カルボキシマルトース第2鉄、その他)分析、用途別(慢性腎臓病、炎症性腸疾患、がん、その他疾患)分析、地域別(北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ)分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Allergan, Inc.、AMAG Pharmaceuticals. Inc.、Daiichi Sankyo Company, Ltd.、Sanofi、Fresenius Medical Care AG & Co.、Vifor Pharma Management Ltd.、Pharmacosmos A/S、Shield Therapeutics Plc、American Regent. Inc.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・産業の展望
・世界静脈注射用鉄剤の市場規模:製品別
- 鉄デキストランの市場規模
- 鉄スクロース鉄の市場規模
- カルボキシマルトース第2鉄の市場規模
- その他静脈注射用鉄剤の市場規模
・世界静脈注射用鉄剤の市場規模:用途別
- 慢性腎臓病における市場規模
- 炎症性腸疾患における市場規模
- がんにおける市場規模
- その他疾患における市場規模
・世界静脈注射用鉄剤の市場規模:地域別
- 北米の静脈注射用鉄剤市場規模
- ヨーロッパの静脈注射用鉄剤市場規模
- アジア太平洋の静脈注射用鉄剤市場規模
- 中南米の静脈注射用鉄剤市場規模
- 中東・アフリカの静脈注射用鉄剤市場規模
・競争状況

静脈注射用鉄剤市場の成長と動向

Grand View Research社の最新レポートによると、世界の静脈注射用鉄剤市場規模は2030年までに56億4000万米ドルに達し、予測期間中のCAGRは8.6%を記録すると予測されています。業界の競争は予測期間中も高水準で推移すると予想されます。同市場は、収益シェアの大半をグローバル企業が占めています。さらに、成長機会が新たなプレーヤーを引き付け、競争上の競合をさらに激化させています。市場は断片化されており、大手企業はより大きなシェアを獲得するために、戦略的提携、買収、新薬の上市など、広範な成長戦略を採用しています。

感染症による高い疾病負担は、栄養不良と相まって、この地域の小児の貧血の主な原因の一つとなっています。新型コロナウイルスの大流行も、重症患者の貧血を増加させ、場合によっては低酸素症を引き起こしています。このため、世界中で貧血治療用の鉄剤の需要がさらに高まっています。

貧血の有病率の増加は、様々な婦人科疾患や消化器疾患にも起因しており、静脈内治療の世界的な普及を促進しています。例えば、貧血の全体的な有病率は、非妊娠女性で29.6%、同年齢層の妊娠女性で36.5%です。医療予算の増加と投資の増加により、市場は予測期間中に大きく成長すると予想されます。

経口鉄剤の欠点である胃痛、便秘、食欲不振、吐き気、嘔吐などの消化器系の問題は、患者が静脈注射剤を好む理由となっています。鉄剤の静脈内投与は、体内への鉄の取り込みを増加させ、赤血球造血刺激因子(ESA)の働きを促進し、貧血状態を改善することが示されています。その他の利点としては、心臓の健康が保たれること、透析患者、特に血液透析を受けている患者が使用できることなどが挙げられます。

鉄剤の静脈内投与市場レポートハイライト

– カルボキシマルトース鉄は、用途の増加、副作用の少なさと相まって優れた性能、コストの削減により、2022年の鉄剤静脈内投与業界を独占しました。

– スクロース鉄は2022年に市場で大きなシェアを占めました。重篤なアレルギー反応の発生率が低いことが、これらの薬剤の採用率を高めています。

– CKDおよびCKDに関連した鉄欠乏性貧血の有病率の増加により、慢性腎臓病セグメントが2022年に最大のシェアを占めました。

– 点滴薬の需要が高いこと、消化器疾患、癌、CKDの有病率が増加していることから、2022年には北米が最大の地域シェアを獲得しました。

– アジア太平洋地域は、満たされていない患者ニーズの増加、医療費の増加、定評あるグローバル企業の現地プレゼンスに起因して、予測期間中に最も速い成長を示すと推定されます。

– 主なプレーヤーには、AbbVie Inc.、AMAG Pharmaceuticals (Covis Pharma)、第一三共株式会社、Sanofi、Vifor Pharma Management Ltd. (CSL)、PHARMACY Inc. (CSL)、PHARMACOSMOS A/S、Zydus Groupなどです。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Content

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary research
1.3.5 Sample size for the study on Intravenous Iron Drugs Market
1.3.6 List of Secondary Data Sources
1.4 Information or Data Analysis
1.5 Market Formulation and Validation
1.6 Market Model
1.6.1 Market study, by company market share
1.6.2 Regional analysis
1.7 Research Assumptions
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot, 2022
2.2 Segment Snapshot
2.3 Competitive Snapshot
Chapter 3 Intravenous Iron Drugs Market – Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.1.2 Related/Ancillary market outlook
3.1.2.1 Inflammatory Bowel Disease Treatment Market
3.1.2.2 Anemia Treatment Market
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Increasing prevalence of target diseases
3.2.1.2 Increasing iron deficiency anemia cases
3.2.1.3 Advantages of intravenous iron drugs
3.2.2 Market restraint analysis
3.2.2.1 Adverse effects associated with iron drugs
3.2.2.2 Increasing approvals of oral iron drugs
3.3 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.4 Industry Analysis – Porter’s
3.5 COVID-19 Impact Analysis
Chapter 4 Intravenous Iron Drugs Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
4.1 Intravenous Iron Drugs Market: Product Movement Analysis
4.2 Intravenous Iron Drugs Market Estimates & Forecast, by Product (USD Million)
4.2.1 Iron Dextran
4.2.2 Iron Sucrose
4.2.3 Ferric Carboxymaltose
4.2.4 Others
Chapter 5 Intravenous Iron Drugs Market – Segment Analysis, by Application, 2018 – 2030 (USD Million)
5.1 Intravenous Iron Drugs Market: Application Movement Analysis
5.2 Intravenous Iron Drugs Market Estimates & Forecast, by Application (USD Million)
5.2.1 Chronic Kidney Disease
5.2.2 Inflammatory Bowel Disease
5.2.3 Cancer
5.2.4 Other Diseases
Chapter 6 Intravenous Iron Drugs Market: Regional Estimates and Trend Analysis
6.1 Intravenous Iron Drugs Market: Regional Outlook
6.2 North America
6.2.1 North America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 U.S. Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.2.2.3 Target Disease Prevalence
6.2.2.4 Market & Competitive Scenario
6.2.2.5 Regulatory Framework
6.2.2.6 Reimbursement Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Canada Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.2.3.3 Target Disease Prevalence
6.2.3.4 Market & Competitive Scenario
6.2.3.5 Regulatory Framework
6.2.3.6 Reimbursement Scenario
6.3 Europe
6.3.1 Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 UK Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.2.3 Target Disease Prevalence
6.3.2.4 Market & Competitive Scenario
6.3.2.5 Regulatory Framework
6.3.2.6 Reimbursement Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Germany Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.3.3 Target Disease Prevalence
6.3.3.4 Market & Competitive Scenario
6.3.3.5 Regulatory Framework
6.3.3.6 Reimbursement Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 France Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.4.3 Target Disease Prevalence
6.3.4.4 Market & Competitive Scenario
6.3.4.5 Regulatory Framework
6.3.4.6 Reimbursement Scenario
6.3.5 Italy
6.3.5.1 Key Country Dynamics
6.3.5.2 Italy Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.5.3 Target Disease Prevalence
6.3.5.4 Market & Competitive Scenario
6.3.5.5 Regulatory Framework
6.3.5.6 Reimbursement Scenario
6.3.6 Spain
6.3.6.1 Key Country Dynamics
6.3.6.2 Spain Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.6.3 Target Disease Prevalence
6.3.6.4 Market & Competitive Scenario
6.3.6.5 Regulatory Framework
6.3.6.6 Reimbursement Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Denmark Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.7.3 Target Disease Prevalence
6.3.7.4 Market & Competitive Scenario
6.3.7.5 Regulatory Framework
6.3.7.6 Reimbursement Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Sweden Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.8.3 Target Disease Prevalence
6.3.8.4 Market & Competitive Scenario
6.3.8.5 Regulatory Framework
6.3.8.6 Reimbursement Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Norway Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.9.3 Target Disease Prevalence
6.3.9.4 Market & Competitive Scenario
6.3.9.5 Regulatory Framework
6.3.9.6 Reimbursement Scenario
6.3.9.7 Rest of Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Japan Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2.3 Target Disease Prevalence
6.4.2.4 Market & Competitive Scenario
6.4.2.5 Regulatory Framework
6.4.2.6 Reimbursement Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 China Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.3.3 Target Disease Prevalence
6.4.3.4 Market & Competitive Scenario
6.4.3.5 Regulatory Framework
6.4.3.6 Reimbursement Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 India Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.4.3 Target Disease Prevalence
6.4.4.4 Market & Competitive Scenario
6.4.4.5 Regulatory Framework
6.4.4.6 Reimbursement Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Australia Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.5.3 Target Disease Prevalence
6.4.5.4 Market & Competitive Scenario
6.4.5.5 Regulatory Framework & Reimbursement Scenario
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.6.3 Target Disease Prevalence
6.4.6.4 Market & Competitive Scenario
6.4.6.5 Regulatory Framework
6.4.6.6 Reimbursement Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.7.3 Target Disease Prevalence
6.4.7.4 Market & Competitive Scenario
6.4.7.5 Regulatory Framework/Reimbursement Scenario
6.4.7.6 Rest of Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Brazil Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2.3 Target Disease Prevalence
6.5.2.4 Market & Competitive Scenario
6.5.2.5 Regulatory Framework
6.5.2.6 Reimbursement Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.3.3 Target Disease Prevalence
6.5.3.4 Market & Competitive Scenario
6.5.3.5 Regulatory Framework
6.5.3.6 Reimbursement Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Argentina Intravenous Iron Drugs Market Estimates and forecasts, 2018 – 2030 (USD Million)
6.5.4.3 Target Disease Prevalence
6.5.4.4 Market & Competitive Scenario
6.5.4.5 Regulatory Framework
6.5.4.6 Reimbursement Scenario
6.5.4.7 Rest of Latin America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.6 MEA
6.6.1 MEA Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2.3 Target Disease Prevalence
6.6.2.4 Market & Competitive Scenario
6.6.2.5 Regulatory Framework
6.6.2.6 Reimbursement Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.3.3 Target Disease Prevalence
6.6.3.4 Market & Competitive Scenario
6.6.3.5 Regulatory Framework
6.6.3.6 Reimbursement Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.4.3 Target Disease Prevalence
6.6.4.4 Market & Competitive Scenario
6.6.4.5 Regulatory Framework
6.6.4.6 Reimbursement Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.5.3 Target Disease Prevalence
6.6.5.4 Market & Competitive Scenario
6.6.5.5 Regulatory Framework
6.6.5.6 Reimbursement Scenario
6.6.5.7 Rest of MEA Intravenous Iron Drugs Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Allergan, Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic initiatives
7.4.2 AMAG Pharmaceuticals. Inc.
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic initiatives
7.4.3 Daiichi Sankyo Company, Ltd.
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic initiatives
7.4.4 Sanofi
7.4.4.1 Company overview
7.4.4.2 Financial performance
7.4.4.3 Product benchmarking
7.4.4.4 Strategic initiatives
7.4.5 Fresenius Medical Care AG & Co.
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic initiatives
7.4.6 Vifor Pharma Management Ltd.
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic initiatives
7.4.7 Pharmacosmos A/S
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic initiatives
7.4.8 Shield Therapeutics Plc
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic initiatives
7.4.9 American Regent. Inc.
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic initiatives

List of Tables

Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies/technology disruptors/innovators
Table 3 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 4 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 5 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 8 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 9 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 10 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 11 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 12 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 13 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 14 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 15 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 16 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 17 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 18 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 19 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 20 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 21 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 22 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 23 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 24 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 25 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 26 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 27 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 28 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 29 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 30 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 31 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 32 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 33 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 34 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 35 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 36 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 37 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 38 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 39 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 40 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 41 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 42 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 43 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 44 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 45 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 46 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 47 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 48 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 49 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 50 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 51 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 52 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 53 MEA intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 54 MEA intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 55 MEA intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 56 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 57 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 60 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 61 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 62 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 63 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

★調査レポート[世界の静脈注射用鉄剤市場2023-2030:製品別(鉄デキストラン、鉄スクロース鉄、カルボキシマルトース第2鉄)、用途別(慢性腎臓病、炎症性腸疾患、がん)、地域別] (コード:GRV23JUN062)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の静脈注射用鉄剤市場2023-2030:製品別(鉄デキストラン、鉄スクロース鉄、カルボキシマルトース第2鉄)、用途別(慢性腎臓病、炎症性腸疾患、がん)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆